A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 06 Mar 2018 Planned End Date changed from 31 Jan 2019 to 27 Feb 2019.
- 06 Mar 2018 Planned primary completion date changed from 31 Jan 2019 to 3 Sep 2018.
- 10 Nov 2017 Planned End Date changed from 23 Jul 2018 to 31 Jan 2019.